GeNeuro SA Stock price

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Real-time Euronext Paris 12:35:14 2024-03-28 pm EDT 5-day change 1st Jan Change
1.38 EUR +6.15% Intraday chart for GeNeuro SA +9.52% +26.61%
Sales 2023 * - Sales 2024 * 28.2M 30.46M Capitalization 40.84M 44.11M
Net income 2023 * -11M -11.88M Net income 2024 * 1M 1.08M EV / Sales 2023 * -
Net Debt 2023 * 13M 14.04M Net Debt 2024 * 7.9M 8.53M EV / Sales 2024 * 1.73 x
P/E ratio 2023 *
-3.21 x
P/E ratio 2024 *
46 x
Employees 19
Yield 2023 *
-
Yield 2024 *
-
Free-Float 73.47%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.15%
1 week+9.52%
Current month+8.24%
1 month+9.96%
3 months+32.06%
6 months-3.16%
Current year+26.61%
More quotes
1 week
1.26
Extreme 1.26
1.38
1 month
1.09
Extreme 1.085
1.38
Current year
1.05
Extreme 1.05
1.70
1 year
0.94
Extreme 0.94
2.38
3 years
0.94
Extreme 0.94
6.28
5 years
0.94
Extreme 0.94
6.28
10 years
0.94
Extreme 0.94
13.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 05-12-31
Founder 66 05-12-31
Director of Finance/CFO 62 15-10-31
Members of the board TitleAgeSince
Director/Board Member 63 21-05-26
Director/Board Member 81 08-07-15
Director/Board Member 75 15-03-16
More insiders
Date Price Change Volume
24-03-28 1.38 +6.15% 11,140
24-03-27 1.3 0.00% 3,304
24-03-26 1.3 +1.17% 4,311
24-03-25 1.285 0.00% 5,013
24-03-22 1.285 +1.98% 2,914

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.38 EUR
Average target price
4 EUR
Spread / Average Target
+189.86%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock GeNeuro SA - Euronext Paris